TEM: Post-Catalyst Consolidation Outweighs Bullish Engine Read
Published · entry price $64.66 · machine-generated by the QuantLogix Thesis Engine and graded publicly at T+7/30/90 days · TEM charts & signals →
Tempus AI (TEM) at $64.66 sits in a no-man's-land between a heavily bearish analyst consensus and a bullish 5-factor quant engine. The 20d momentum spike from the Moderna Phase 3 win is bleeding off, blocked by a bearish SMA trend and an unverified long-side cohort, forcing a WATCH verdict. We require a weekly close above $72.70 to confirm the breakout or a break below $58.00 to trigger the bearish gap-retrace.
Thesis
- A weekly close below $58.00 retraces the post-INTerpath-001 gap and invalidates the momentum-driven re-rating thesis.
- Failure to close the $1.5B Personalis acquisition by Q1 2027 invalidates the strategic sequencing layer narrative.
- The stock must hold above $64.66 to prevent the 5d momentum (-9.55%) from dragging the 20d momentum (32.63%) into a bearish crossover. — triggered 09/03/2026
Evidence Graph3 of 3 claims linked · 2 preserved sources
This graph uses only evidence frozen into the thesis at publication on 09/03/2026. “Retrieved source passage” is the preserved grounding excerpt the engine saw; “published note passage” is thesis context, not a source quote. Missing edges and dates remain visible.
Conviction history
1 change- MEDIUM → LOW
The TEM thesis is now closed as the stock price has hit the $64.66 invalidation level. This decline triggers a bearish crossover, nullifying the previous outlook.
A weekly close below $58.00 retraces the post-INTerpath-001 gap and invalidates the momentum-driven re-rating thesis.
FrontierPicks explicitly sets the kill line at a weekly close below $58, returning price to the pre-catalyst shelf.
Retrieved source passage
TEM stock analysis — Tempus AI, Inc. — FrontierPicks Sections Current thesis Second-order re-rating: Merck/Moderna's 2026-08-19 Phase 3 INTerpath-001 win — the first positive readout for an individualised neoantigen therapy — repriced TEM as the listed owner of the MRD sequencing layer via its pending $1.5B Personalis deal. Price closed $72.69 on 2026-08-21 with RSI 82.4 and no dated binary inside 30 days. Kill line A weekly close below $58 retraces the entire 2026-08-19 post-readout gap and returns price to the pre-catalyst shelf; secondary condition — a Personalis proxy or antitrust delay pushing the close past Q1 2027, or full INTerpath-001 data presented with no Personalis assay in the w
Failure to close the $1.5B Personalis acquisition by Q1 2027 invalidates the strategic sequencing layer narrative.
Identifies deal delays or proxy failures as a secondary thesis killer.
Retrieved source passage
TEM stock analysis — Tempus AI, Inc. — FrontierPicks Sections Current thesis Second-order re-rating: Merck/Moderna's 2026-08-19 Phase 3 INTerpath-001 win — the first positive readout for an individualised neoantigen therapy — repriced TEM as the listed owner of the MRD sequencing layer via its pending $1.5B Personalis deal. Price closed $72.69 on 2026-08-21 with RSI 82.4 and no dated binary inside 30 days. Kill line A weekly close below $58 retraces the entire 2026-08-19 post-readout gap and returns price to the pre-catalyst shelf; secondary condition — a Personalis proxy or antitrust delay pushing the close past Q1 2027, or full INTerpath-001 data presented with no Personalis assay in the w
Invezz notes the Personalis deal failing would prevent strategic asset validation.
Retrieved source passage
Tempus AI stock is soaring and it has Moderna to thank Tempus AI stock is soaring and it has Moderna to thank AI Sentiment: 82/100 Bullish This score is generated through AI-driven analysis of the article's content. Author Aug 19, 2026, 15:47 PM Generate Trading IdeasGenerating powered by TEM (Tempus AI) Buy TEM. Merck/Moderna Phase 3 success validates the sequencing tech Personalis feeds into, flipping the acquisition-dilution narrative into “strategic asset proven.” The stock also broke above major moving averages with heavy volume, and short interest (~20%) plus RSI mid-60s supports momentum into the $65 area. Thesis killer: Personalis deal/regulatory approval stalls or fails, preventin
The stock must hold above $64.66 to prevent the 5d momentum (-9.55%) from dragging the 20d momentum (32.63%) into a bearish crossover.
Highlights heavy volume and short interest dynamics that dictate the current technical support level.
Retrieved source passage
Tempus AI stock is soaring and it has Moderna to thank Tempus AI stock is soaring and it has Moderna to thank AI Sentiment: 82/100 Bullish This score is generated through AI-driven analysis of the article's content. Author Aug 19, 2026, 15:47 PM Generate Trading IdeasGenerating powered by TEM (Tempus AI) Buy TEM. Merck/Moderna Phase 3 success validates the sequencing tech Personalis feeds into, flipping the acquisition-dilution narrative into “strategic asset proven.” The stock also broke above major moving averages with heavy volume, and short interest (~20%) plus RSI mid-60s supports momentum into the $65 area. Thesis killer: Personalis deal/regulatory approval stalls or fails, preventin
What changed
Complete, timestamped thesis history.
-
Invalidation rule triggeredThe TEM thesis is now closed as the stock price has hit the $64.66 invalidation level. This decline triggers a bearish crossover, nullifying the previous outlook. · $64.66
-
Thesis publishedWATCH · LOW conviction
Setup
Tempus AI (TEM) is currently a battleground between fundamental narrative momentum and technical exhaustion. The stock spiked heavily on the 2026-08-19 Phase 3 INTerpath-001 trial success for Merck/Moderna, which validated TEM's sequencing technology via its pending $1.5B acquisition of Personalis. However, at a current price of $64.66, TEM is down sharply from its $72.69 peak on 2026-08-21. The platform's composite signal is Neutral (score 0), caught between a Strong Buy from the LIVE 5-factor engine (composite 76/100) and a Strong Sell from analyst consensus with a price target of $40.94.
Evidence & Data
The technical stack is actively deteriorating. RSI has cooled to 54.3, MACD is negative at -0.085, and 5d momentum is -9.55%, all signaling that the post-catalyst euphoria is fading. While the 20d momentum remains high at 32.63%, the SMA trend is bearish. News sentiment sits slightly negative at -0.1. Furthermore, the options flow shows no large positioning or whale orders, indicating institutional conviction is absent at these levels.
The consensus view is a Strong Sell with a price target of $40.94, reflecting concerns over valuation and acquisition dilution. This thesis believes the market is currently mispricing the timeline and integration risk of the Personalis deal. The variant perception is that the 20d momentum is a lagging indicator of a binary event (the Phase 3 win) rather than a durable trend, and the unverified long-side cohort (62.3% win over 355 signals) prevents us from running a bullish verdict against the bearish SMA trend.
Scenario Analysis
| Scenario | Probability | Price path | Thesis impact |
|---|---|---|---|
| Bullish Breakout | 25% | Rallies to close above $72.70 | Validates engine read; triggers BULLISH re-rating |
| Consolidation | 45% | Trades sideways between $58.00 and $72.00 | WATCH thesis holds; deal closes on schedule |
| Bearish Gap-Retrace | 30% | Fails to hold $58.00 weekly | Invalidates momentum; reverts to pre-catalyst shelf |
EV = 0.25×$80.00 + 0.45×$64.66 + 0.30×$50.00 = $64.30, ±0.6% vs current
Catalysts & Risks
The primary catalyst is the successful closure of the $1.5B Personalis acquisition, which would solidify TEM as the listed owner of the MRD sequencing layer. A delay past Q1 2027 or an antitrust block would immediately invalidate the thesis. The primary risk is investor myopia; data licensing revenues rose nearly 70% last quarter, but management projects a 25% CAGR with only 4% adjusted EBITDA, meaning the stock is highly sensitive to any miss in high-margin growth.
What Changes Our Mind
Given that 4 of the last 6 engine theses were invalidated on their own claims, we have set our invalidation levels wider of obvious support/resistance. We will upgrade TEM to BULLISH if it achieves a daily close above $72.70 on high volume, confirming the breakout against the bearish SMA trend. We will downgrade to BEARISH if it records a weekly close below $58.00, which would retrace the entire post-readout gap and confirm the inverted short-side cohort's bearish drift signal. Until either trigger fires, the asymmetric risk/reward mandates a WATCH rating.
Related QuantLogix coverage
- $CRDO Hits Perfect 100/100 — Engine Flags Strong Buy at $255 | QuantLogix
- $TER Hits 100/100 Composite — Engine Flags Strong Buy at $432 | QuantLogix
- Shein IPO 2026 — The Hong Kong Listing at $30–50B, $38B Revenue, the Post-Tariff Reset
More from QL Research
- DATABENTO · WATCH — Databento (Private): Pre-IPO Infrastructure Thesis
- AVY · WATCH — AVY: Bearish Technicals and Inverted Cohort Math Override Fundamental Value
- MTZ · WATCH — MTZ: Mean-Reversion Exhausted, Fundamentals Unconfirmed — WATCH
- MDLN · WATCH — MDLN: Margin Compression Meets Premium Multiple — WATCH
- REPLIT · WATCH — REPLIT (Private) — WATCH: $9B Valuation Stretched on Growth Optics, Unconfirmed on Fundamentals
- SCCO · WATCH — SCCO: Record EBITDA Meets Record Multiples — WATCH